Evofem Biosciences, Inc. (EVFM)
OTCMKTS
· Delayed Price · Currency is USD
0.0098
-0.0002 (-2.00%)
Jun 4, 2025, 2:09 PM EDT
Evofem Biosciences Revenue
Evofem Biosciences had revenue of $845.00K in the quarter ending March 31, 2025, a decrease of -76.55%. This brings the company's revenue in the last twelve months to $16.61M, up 3.70% year-over-year. In the year 2024, Evofem Biosciences had annual revenue of $19.36M with 6.28% growth.
Revenue (ttm)
16.61M
Revenue Growth
+3.70%
P/S Ratio
0.07
Revenue / Employee
518.91K
Employees
32
Market Cap
1.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.36M | 1.15M | 6.28% |
| Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
| Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
| Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
| Dec 31, 2020 | 446.00K | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
| American Oncology Network | 1.76B |
Evofem Biosciences News
- 15 days ago - Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1 - PRNewsWire
- 21 days ago - Evofem Biosciences GAAP EPS of $0.00, revenue of $0.85M - Seeking Alpha
- 21 days ago - Evofem Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Evofem Biosciences to Present at Emerging Growth Conference - PRNewsWire
- 2 months ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 2 months ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 2 months ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 3 months ago - Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO - PRNewsWire